Lobe Sciences Ltd. Acquires Altemia & Company, LLC

Afya Limited Acquires Além da Medicina

March 4, 2022

Education

Afya Limited, through its wholly-owned subsidiary Afya Participações S.A., has completed the acquisition of 100% of Além da Medicina for an enterprise value of R$16.0 million paid in cash, with an additional earn-out of up to R$19.2 million tied to revenue targets for 2023–2024. Além da Medicina is a Brazilian online medical content and education platform serving physicians and medical students (more than 4,000 subscribers in 2021) and the deal is intended to strengthen Afya's digital content and medical education capabilities.

Ipsen Acquires Albireo Pharma

January 9, 2023

Biotechnology

Ipsen has agreed to acquire Albireo Pharma in a cash tender offer of $42.00 per share plus a contingent value right (CVR) tied to FDA approval in biliary atresia, in a transaction intended to expand Ipsen's Rare Disease portfolio. The acquisition brings Albireo's approved pediatric liver drug Bylvay (odevixibat) and a pipeline of bile-acid modulators into Ipsen's global R&D and commercial capabilities.

Lantheus Acquires Life Molecular Imaging from Life Healthcare

July 22, 2025

Healthcare Services

Lantheus Holdings, Inc. completed the acquisition of Life Molecular Imaging Ltd., a subsidiary of Life Healthcare Group Holdings Ltd., gaining the Neuraceq (florbetaben F18) commercial product, expanded Alzheimer’s radiodiagnostic infrastructure, and additional R&D capabilities. As part of the transaction, Dr. Ludger Dinkelborg (formerly CEO of Life Molecular) will join Lantheus as Head of Research & Development, reporting to the CEO.

Calian Group Acquires Allphase Clinical Research and Alio Health Services

January 31, 2020

Healthcare Services

Calian Group Ltd. announced the acquisition of Ottawa-based Allphase Clinical Research Services Inc. and Alio Health Services Inc., bringing clinical trial management, patient support program capabilities and a proprietary home-care scheduling software into Calian’s Health segment. The deal consideration included $12.0 million in cash, 62,054 common shares and up to $12.0 million of earnouts tied to future EBITDA, with Calian planning to integrate the HOMETM application across its health services to drive new business and efficiencies.

Aileron Therapeutics Acquires Lung Therapeutics

October 31, 2023

Biotechnology

Aileron Therapeutics, Inc. (NASDAQ: ALRN) completed a stock-for-stock acquisition of Lung Therapeutics, Inc., bringing the clinical-stage pulmonary and fibrosis-focused pipeline (including lead candidate LTI-03) into Aileron's portfolio. Immediately after the acquisition Aileron arranged a private placement led by Bios Partners (with participation from Nantahala Capital and others) to raise approximately $18 million to fund ongoing development, including a Phase 1b trial of LTI-03.

Astorg to Acquire Majority Stake in Solabia Group

May 7, 2025

Biotechnology

Astorg has signed a definitive agreement to acquire a majority stake in Solabia Group from TA Associates, with TA reinvesting alongside Astorg. Solabia, a Paris-headquartered biotech ingredients manufacturer with 11 production sites, 8 R&D labs and over 900 employees, will partner with Astorg to accelerate international expansion (particularly in the US and Asia), advance product innovation and pursue targeted M&A.